By FieldPulse Editorial · February 10, 2026
Tags: biosimilars, compensation, abbvie
AbbVie Humira U.S. net revenues dropped 27.9% in Q4 2025 as biosimilar adalimumab competition continued to accelerate. Skyrizi grew 50% and Rinvoq 39% full-year to offset the decline.
AbbVie reported Q4 2025 earnings showing Humira U.S. net revenues down 27.9% year-over-year as biosimilar adalimumab competition continued to accelerate. Full-year 2025 Humira U.S. revenues declined 57.1% compared to 2024 as high-concentration biosimilars from Amgen, Sandoz, and Boehringer Ingelheim captured an increasing share of new prescriptions. For the full year, Skyrizi grew approximately 50% and Rinvoq grew 39%, collectively more than offsetting the Humira erosion and driving overall AbbVie immunology revenue growth. AbbVie reiterated its long-term guidance, with Skyrizi and Rinvoq expe